The value of 18F-FDG PET/CT in patient with neurofibromatosis type 1
A case report and literature review

Jiazhong Ren, MD\textsuperscript{a}, Guoren Yang, MD\textsuperscript{b,e}, Jing Zhou, MD\textsuperscript{c,e}, Zheng Fu, MD\textsuperscript{d,e,*}

Abstract
Rationale: Neurofibromatosis type one (NF1) is characterized by cutaneous and nervous lesions, and the tendency to form plexiform neurofibromas (PNFs). PNFs may undergo malignant transformation into a malignant peripheral nerve sheath tumours (MPNSTs). MPNSTs often carry significant morbidity and mortality.

Patient concerns: A 17-year-old man with gradually increased multiple subcutaneous soft lesions. He also presented with numerous lentigines and multiple café-au-lait macules on his body.

Diagnoses: These were collagen neurofibroma, which were definitively diagnosed by pathology. NF1 was eventually diagnosed.

Interventions: These lesions were abnormal uptake of radiotracer, when he underwent positron emission tomography (PET) with fluordeoxymine-18-fluorodeoxyglucose (FDG) scanning. Standard uptake value (SUV) and other parameters can help to distinguish benign and malignant lesions in patient with NF1. He was underwent serials 18F-FDG PET/CT examinations to followed up, in order to monitor these lesions malignant transformation.

Outcomes: So far, these subcutaneous soft lesions were not malignant transformation.

Lessons: 18F-FDG PET/CT is being increasingly used as an imaging modality to discover the systemic lesions and to discriminate between benign and malignant plexiform neurofibromas.

Abbreviations: BAT = brown adipose tissue, FDG = fluordeoxymine-18-fluorodeoxyglucose, MPNST = malignant peripheral nerve sheath tumours, NF1 = neurofibromatosis type 1, PET = positron emission tomography, PNF = plexiform neurofibroma, SUV = standardized uptake value.

Keywords: 18F-FDG PET/CT, café-au-lait macules, neurofibromatosis

1. Introduction

Neurofibromatosis type one (NF-1) is a common inherited disorder with an incidence of 1:2500 to 1:3000, which characterized by cutaneous and nervous lesions, and the tendency to form plexiform neurofibromas (PNFs). And more worryingly, many PNFs may undergo malignant transformation into a malignant peripheral nerve sheath tumors (MPNSTs). However, MPNSTs carry a significant morbidity and mortality owing to delayed diagnosis, local recurrence, early metastasis, and poor therapeutic effect. Medical imaging can lead to earlier diagnosis and improve prognosis in patient with NF1. Magnetic resonance imaging (MRI) can detect MPNST more sensitively and specificity, which can provide a complete characterization of the genesis, growth dynamics, and the range of nerve sheath tumors. And whole-body MRI is more suited to serial follow-up in patients with PNFs, owing to its no radiation exposure.\textsuperscript{1,11} 18F-FDG PET/CT usually provides a high sensitivity and specificity for monitoring malignant lesions, particularly for staging and restaging in patient with tumor, in order to change therapy planning in time and improve prognosis. Our aim is to discuss the role of 18F-FDG PET/CT in NF1 patients.

2. Case report

A 17-year-old man presented with an increase in the size and number of cutaneous lesions (Fig. 1A) and subcutaneous soft lesions. 18F-FDG PET/CT has been underwent which showed diffuse hypermetabolic foci of the neck, clavicular region, near iliac vessels of left, near piriformis, and gastrocnemius of left leg. The hypermetabolic tissue in pharynx was physiological (Fig. 1C). And hypermetabolic tissues in clavicular region was brown adipose tissue (BAT) (Fig. 1D), because of this young man was too thin and underwent 18F-FDG PET/CT in winter.\textsuperscript{1,12} The lesions under sternocleidomastoid (Fig. 1C), gastrocnemius (Fig. 1E) of left were neurogenic tumors, which were benign neurofibroma (Fig. 1B) by pathology.

The standardized clinical diagnostic criteria of NF1, which have existed since 1987.\textsuperscript{14} Many numerous lentigines and multiple café-au-lait macules on his father were founded. So, NF1 of this young man was eventually diagnosed.
For mean tumor SUV, the SUV was calculated for SUVmax is 4.0 that can predict the optimal cutoff of malignant and 0.94 to distinguish between benign and malignant lesions. The cutoff SUVmax value of 4.0 had high sensitivity and specificity.

Some scholars found that the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT have positive correlation with malignant transformation. BAT (D). BAT = brown adipose tissue, FDG = fluorine-18-fluorodeoxyglucose, PET = positron emission tomography.

The patient has consented for the publication of the present case report.

3. Discussion

The tumor suppressor gene mutation in chromosome 17, was considered as the reason of NF1. The terrible results may be occurred, for instance the development of malignant tumors, because gene mutation. Many pathological types of tumor may be occurred in NF1 patient. Patients with NF1 have a cumulative lifetime risk of approximately 10% for developing an MPNST versus <0.1% for the general population. MPNST is a life-threatening disease, which has poor prognosis. Therefore, a definite and early distinguish lesion was significant.

Standard uptake value (SUV) can help to distinguish benign and malignant lesions in patient with NF1. Some scholars found that the SUVmax of benign lesions (2.49) was significantly different from malignant lesions (7.63) in pediatric population, respectively. A cutoff SUVmax value of 4.0 had high sensitivity and specificity of 1.0 and 0.94 to distinguish between benign and malignant lesions. The SUVmax is 4.0 that can predict the optimal cutoff of malignant transformation. For mean tumor SUV, the SUV was calculated for 20 NF1 patients and was obvious higher in 5 malignant tumors 5.4, than in 15 benign tumors 1.54. Some tumors were difficult to distinguish benign or malignant, when the SUV between 2.7 and 3.3. The mean survival time was 13 months for patients with an SUV >3, compared with 52 months, for whom with an SUV <3. What’s more, SUV has been had a significantly higher accuracy (94%), than tumor grade (69%), when they predicted long-term survival.

SUV is a unitless semiquantitative measure of FDG. Several factors, for instance, ambient temperature, body weight, respiratory effort, blood glucose level, and the amount of time between injection of radionuclide and scanning, may affect the SUV measurement. These factors may interfere with diagnosis. Novel parameters such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been used which have shown promise but lack enough evidence to justify routine use. Further research is needed to study for precise diagnosis. It had the important significance of 18F-FDG PET/CT in diagnosis and differential diagnosis the lesion nature in patient with NF1. These can impact on treatment and prognosis of patient with NF1.

Author contributions

Conceptualization: jing zhou.
Data curation: zheng fu.
Investigation: zheng fu.
Resources: zheng fu.
Supervision: zheng fu.
Writing – original draft: JIAZHONG REN, jing zhou.
Writing – review & editing: guoren yang, zheng fu.

References

[1] Salamon J, Mautner VF, Adam G, et al. Multimodal imaging in neurofibromatosis type 1-associated nerve sheath tumors. Rofo 2015;187:1064–92.
[2] Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2007;293:E444–52.
[3] Ouellet V, Routhier-Labadie A, Bellemare W, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab 2011;96:192–9.
[4] National Institutes of Health Consensus Development ConferenceNeurofibromatosis. Arch Neurol (Chicago) 1988;45:575–8.
[5] Malhotra A, Wright J, Gajra A. Extra gastrointestinal stromal tumor treated with imatinib in a patient with neurofibromatosis type 1. J Gastrointest Oncol 2012;3:373–6.
[6] Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics 2009;123:124–33.
[7] Evans DG, Baser ME, McLaughlan J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311–4.
[8] Tsai LL, Drubach L, Fahey F, et al. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol 2012;108:469–75.
[9] Tsai LL, Drubach L, Fahey F, et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with...
neurofibromatosis type 1: a systematic review. Radiol Res Pract 2012;2012:431029.

[10] Ferner RE, Lucas JD, O’Doherty MJ, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000;68:353–7.

[11] Brenner W, Friedrich RE, Gawad KA, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006;33:428–32.

[12] Tovmassian D, Abdul Razak M, London K. The role of [18F] FDG-PET/CT in predicting malignant transformation of plexiform neurofibromas in neurofibromatosis-1. Int J Surg Oncol 2016;2016:6162182.